Deerfield Management Company, L.P. (Series C) Arrowhead Pharmaceuticals, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 26,439 shares of ARWR stock, worth $501,283. This represents 0.01% of its overall portfolio holdings.
Number of Shares
26,439
Previous 19,461
35.86%
Holding current value
$501,283
Previous $505,000
1.19%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding ARWR
# of Institutions
294Shares Held
90.8MCall Options Held
155KPut Options Held
426K-
Black Rock Inc. New York, NY15.7MShares$297 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$232 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.89MShares$169 Million2.59% of portfolio
-
State Street Corp Boston, MA6.35MShares$120 Million0.01% of portfolio
-
Slate Path Capital LP New York, NY4.89MShares$92.6 Million1.49% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $2.01B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...